Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 36, 2015, Pages 11335-11340

  Bowen, Anthony ^a   Casadevall, Arturo ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biomedical research; Health outcomes; Innovation; Research efficiency

Indexed keywords

ARTICLE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HUMAN; INVESTMENT; LIFE EXPECTANCY; MEDICAL RESEARCH; MEDLINE; MILITARY RESEARCH; PRIORITY JOURNAL; PUBLICATION; SOCIETY; SPECIALIZATION; SYSTEMATIC REVIEW; FORECASTING; HEALTH CARE PLANNING; NATIONAL HEALTH ORGANIZATION; PRODUCTIVITY; PUBLIC HEALTH; STANDARDS; STATISTICS AND NUMERICAL DATA; TRANSLATIONAL RESEARCH; TRENDS; UNITED STATES;

BIOMEDICAL RESEARCH; EFFICIENCY; FORECASTING; HEALTH RESOURCES; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PUBLIC HEALTH; PUBLICATIONS; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84941254141     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1504955112     Document Type: Article

References (80)

1. Witzel M (2002) A short history of efficiency. Bus Strateg Rev 13(4):38-47.
2. Hirsch JE (2005) An index to quantify an individual's scientific research output. Proc Natl Acad Sci USA 102(46):16569-16572.
3. Brembs B, Button K, Munafò M (2013) Deep impact: Unintended consequences of journal rank. Front Hum Neurosci 7:291.
4. Casadevall A, Fang FC (2014) Causes for the persistence of impact factor mania. MBio 5(2):e00064-e14.
5. Ioannidis JPA (2005) Why most published research findings are false. PLoS Med 2(8):e124.
6. Begley CG, Ellis LM (2012) Drug development: Raise standards for preclinical cancer research. Nature 483(7391):531-533.
7. Prinz F, Schlange T, Asadullah K (2011) Believe it or not: How much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10(9):712.
8. Freedman LP, Cockburn IM, Simcoe TS (2015) The economics of reproducibility in preclinical research. PLoS Biol 13(6):e1002165.
9. Collins FS, Tabak LA (2014) Policy: NIH plans to enhance reproducibility. Nature 505(7485):612-613.
10. Casadevall A, Fang FC (2009) Important science: It's all about the SPIN. Infect Immun 77(10):4177-4180.
11. Bornmann L (2012) Measuring the societal impact of research: Research is less and less assessed on scientific impact alone-We should aim to quantify the increasingly important contributions of science to society. EMBO Rep 13(8):673-676.
12. Ashby N (2003) Relativity in the global positioning system. Living Rev Relativity 6(1):1-42.
13. National Institutes of Health (2013) Mission. Available at perma.cc/H7EP-F42S. Accessed June 7, 2015.
14. Fang FC, Steen RG, Casadevall A (2012) Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci USA 109(42):17028-17033.
15. Steen RG, Casadevall A, Fang FC (2013) Why has the number of scientific retractions increased? PLoS One 8(7):e68397.
16. US Food and Drug Administration (2015) New drugs at FDA: CDER's New Molecular Entities and New Therapeutic Biological Products. Available at perma.cc/Z8LX-3Q9E. Accessed March 6, 2015.
17. Chakma J, Sun GH, Steinberg JD, Sammut SM, Jagsi R (2014) Asia's ascent-global trends in biomedical R&D expenditures. N Engl J Med 370(1):3-6.
18. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JPA (2008) Medicine. Life cycle of translational research for medical interventions. Science 321(5894):1298-1299.
19. Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JPA (2003) Translation of highly promising basic science research into clinical applications. Am J Med 114(6):477-484.
20. Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11(3):191-200.
21. Barham BL, Foltz JD, Prager DL (2014) Making time for science. Res Policy 43(1):21-31.
22. Ledford H (2015) Congress seeks to quash patent trolls. Nature 521(7552):270-271.
23. Seok J, et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110(9):3507-3512.
24. Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126.
25. Geraghty RJ, et al.; Cancer Research UK (2014) Guidelines for the use of cell lines in biomedical research. Br J Cancer 111(6):1021-1046.
26. Casadevall A, Fang FC (2014) Specialized science. Infect Immun 82(4):1355-1360.
27. Papatheodorou SI, Trikalinos TA, Ioannidis JPA (2008) Inflated numbers of authors over time have not been just due to increasing research complexity. J Clin Epidemiol 61(6):546-551.
28. Casadevall A, Steen RG, Fang FC (2014) Sources of error in the retracted scientific literature. FASEB J 28(9):3847-3855.
29. Baker M (2015) Reproducibility crisis: Blame it on the antibodies. Nature 521(7552):274-276.
30. Ioannidis JPA (2015) A generalized view of self-citation: Direct, co-author, collaborative, and coercive induced self-citation. J Psychosom Res 78(1):7-11.
31. Eckartz K, Kirchkamp O, Schunk D (2012) How do incentives affect creativity? CESifo Working Paper Series No. 4049. Available at perma.cc/ET8J-6KWB. Accessed June 19, 2015.
32. Al-Shahi Salman R, et al. (2014) Increasing value and reducing waste in biomedical research regulation and management. Lancet 383(9912):176-185.
33. Young NS, Ioannidis JPA, Al-Ubaydli O (2008) Why current publication practices may distort science. PLoS Med 5(10):e201.
34. Chan A-W, et al. (2014) Increasing value and reducing waste: Addressing inaccessible research. Lancet 383(9913):257-266.
35. Anonymous (2012) Further confirmation needed. Nat Biotechnol 30(9):806.
36. Crow MM (2011) Time to rethink the NIH. Nature 471(7340):569-571.
37. Casadevall A, Fang FC (2012) Reforming science: Methodological and cultural reforms. Infect Immun 80(3):891-896.
38. Fang FC, Casadevall A (2012) Reforming science: Structural reforms. Infect Immun 80(3):897-901.
39. Tuljapurkar S, Li N, Boe C (2000) A universal pattern of mortality decline in the G7 countries. Nature 405(6788):789-792.
40. Mocroft A, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352(9142):1725-1730.
41. Goldman L, Cook EF (1984) The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 101(6):825-836.
42. Collins FS (2010) Revealing the body's deepest secrets. Parade. Available at perma.cc/RWJ4-C456. Accessed June 18, 2015.
43. Jobling MA, Gill P (2004) Encoded evidence: DNA in forensic analysis. Nat Rev Genet 5(10):739-751.
44. Chabner BA, Roberts TG, Jr (2005) Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5(1):65-72.
45. Rosenau J (2012) Science denial: A guide for scientists. Trends Microbiol 20(12):567-569.
46. Achenbach J (2015) Why science is so hard to believe. The Washington Post. Available at perma.cc/7N96-DV7E. Accessed March 6, 2015.
47. US National Library of Medicine PubMed search engine. Available at www.ncbi.nlm. nih.gov/pubmed/. Accessed March 7, 2015.
48. US National Library of Medicine (2014) MEDLINE/PubMed data element (field) descriptions. Available at perma.cc/Q9XL-CNW2. Accessed January 22, 2015.
49. National Institutes of Health (2014) The NIH almanac: Appropriations (section 2). Available at perma.cc/62PJ-F3FS. Accessed January 21, 2015.
50. National Institutes of Health (2013) National Institutes of Health: Operating plan for FY 2014. Available at perma.cc/F3Z5-XEDS. Accessed January 21, 2015.
51. US Bureau of Labor Statistics (2015) CPI detailed report: Data for December 2014. Available at perma.cc/H8SJ-CT2C. Accessed January 21, 2015.
52. Madrick J (2014) Innovation: The government was crucial after all. The New York Review of Books. Available at perma.cc/8J6H-4XXE. Accessed June 18, 2015.
53. US Food and Drug Administration (2013) Summary of NDA approvals & receipts, 1938 to the present. Available at perma.cc/6SSM-W4B7. Accessed January 21, 2015.
54. US Food and Drug Administration (2015) Novel new drugs: 2014 summary. Available at perma.cc/ZN5J-LLGG. Accessed January 29, 2015.
55. The World Health Organization (2004) The World medicines situation. Available at perma.cc/FBH3-XS5X. Accessed February 2, 2015.
56. Hollis A (2004) Me-too drugs: Is there a problem? Available at perma.cc/U4W6-T6VA. Accessed June 18, 2015.
57. The World Bank (2014) World Bank open data. Available at data.worldbank.org. Accessed February 2, 2015.
58. US Patent and Trademark Office (2014) US patent statistics chart. Available at perma. cc/LN2Q-JFGT. Accessed March 7, 2015.
59. European Commission Eurostat (2014) Life expectancy by age and sex. Available at appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo-mlexpec&lang=en. Accessed October 2, 2014.
60. Wilson E (2005) The top pharmaceuticals that changed the world: Thyroxine. Chemical & Engineering News. Available at perma.cc/4Y2Q-U9TT. Accessed February 2, 2015.
61. Santella TM, Wertheimer AI (2005) The levothyroxine spectrum: Bioequivalence and cost considerations. Formulary 40(8):258-271.
62. Fleming A (1980) Classics in infectious diseases: On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929. Rev Infect Dis 2(1):129-139.
63. American Chemical Society (1999) Discovery and development of penicillin. Available at perma.cc/9NRJ-PZXB. Accessed January 21, 2015.
64. Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153(3):586-600.
65. Quirke V (2006) Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978. Med Hist 50(1):69-92.
66. Carr H (1952) Free precession techniques in nuclear magnetic resonance. PhD thesis (Harvard Univ, Cambridge, MA).
67. Mallard J (2003) The evolution of medical imaging: From Geiger counters to MRI-a personal saga. Perspect Biol Med 46(3):349-370.
68. Prince AM (1968) Relation of Australia and SH antigens. Lancet 2(7565):462-463.
69. Gerlich WH (2013) Medical virology of hepatitis B: How it began and where we are now. Virol J 10:239.
70. Erdös EG (2006) The ACE and I: How ACE inhibitors came to be. FASEB J 20(8):1034-1038.
71. Smith CG, Vane JR (2003) The discovery of captopril. FASEB J 17(8):788-789.
72. Jackson DA, Symons RH, Berg P (1972) Biochemical method for inserting new genetic information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA 69(10):2904-2909.
73. Junod SW (2009) Celebrating a milestone: FDA's approval of first geneticallyengineered product. Available at perma.cc/BTN6-LZBZ. Accessed February 2, 2015.
74. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-497.
75. Smith SL (1996) Ten years of Orthoclone OKT3(muromonab-CD3): A review. J Transpl Coord 6(3):109-119, quiz 120-121.
76. Tobert JA (2003) Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2(7):517-526.
77. US Food and Drug Administration (2014) HIV/AIDS historical time line 1981-1990. Available at perma.cc/D7JM-9ZQE. Accessed January 21, 2015.
78. Bartlett JG (2006) Ten years of HAART: Foundations for the future. Medscape. Available at perma.cc/XQS4-FD24. Accessed February 2, 2015.
79. Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 19(7):813-824.
80. Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293-12297.